Exscientia plc (NASDAQ: EXAI) had its price target lowered by analysts at Morgan Stanley from $21.00 to $20.00. They now have an "equal weight" rating on the stock.
Exscientia Plc - American Depositary Shares (EXAI)
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
EXAI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EXAI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EXAI alerts
High impacting Exscientia Plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
EXAI
News
- Neuroimmunology Drugs Market worth $37.32 billion by 2030 - Exclusive Report by InsightAce AnalyticPR Newswire
- Neuroimmunology Drugs Market worth $37.32 billion by 2030 - Exclusive Report by InsightAce AnalyticPR Newswire
- Artificial Intelligence (AI) in Drug Discovery Market worth $4.0 billion by 2027 - Exclusive Report by MarketsandMarkets™PR Newswire
- Artificial Intelligence (AI) in Drug Discovery Market worth $4.0 billion by 2027 - Exclusive Report by MarketsandMarkets™PR Newswire
- Exscientia Reports Topline Data From EXS-21546 Phase 1a Study Demonstrating Targeted A2A Receptor Signaling Inhibition in Healthy VolunteersBusiness Wire
EXAI
Sec Filings
- 5/25/22 - Form 6-K
- 5/20/22 - Form 6-K
- 4/22/22 - Form 6-K
- EXAI's page on the SEC website